Table 3 Treatment-emergent serious adverse events (safety population)
Serious adverse events (SAEs) | Treatment group, 90 mg (n = 8) | Treatment group, 135 mg (n = 5) | Total (N = 13) |
|---|---|---|---|
Patients with any SAE n (%) | 2 (25.0) | 2 (40.0) | 4 (30.8) |
 Anemia | 1 (12.5) | 0 | 1 (7.7) |
 Febrile neutropenia | 0 | 1 (20.0) | 1 (7.7) |
 Leukopenia | 1 (12.5) | 0 | 1 (7.7) |
 Pancytopenia | 0 | 1 (20.0) | 1 (7.7) |
 Thrombocytopenia | 1 (12.5) | 0 | 1 (7.7) |
 Pneumonia | 1 (12.5) | 0 | 1 (7.7) |
 Urosepsis | 0 | 1 (20.0) | 1 (7.7) |
 Peritoneal hemorrhage | 1 (12.5) | 0 | 1 (7.7) |